About 1,870,408 results (3,647 milliseconds)

Immunotherapy delays recurrence for stage III and IV ovarian cancers

http://feedproxy.google.com/~r/sciencedaily/health_medicine/ovarian_cancer/~3/8jal_Oo2fOI/150328102418.htm?utm_source=feedburner&utm_medium=email
Mar 28, 2015 ... An experimental immunotherapy is in the works that can target an individual woman's tumor and extend the time period between initial treatment ...

Study of STRO-002 Shows Promise of ADCs in Ovarian Cancer

https://news.google.com/__i/rss/rd/articles/CBMiWmh0dHBzOi8vd3d3LnRhcmdldGVkb25jLmNvbS92aWV3L3N0dWR5LW9mLXN0cm8tMDAyLXNob3dzLXByb21pc2Utb2YtYWRjcy1pbi1vdmFyaWFuLWNhbmNlctIBAA?oc=5
Sep 15, 2021 ... It is approved in combination with chemoradiotherapy to treatment patients with FIGO 2014 stage III to IVA cervical cancer; in combination ...

New method shrinks metastatic ovarian cancer and reduces ...

http://feedproxy.google.com/~r/sciencedaily/health_medicine/ovarian_cancer/~3/KPPZsQE9E5k/150202105604.htm?utm_source=feedburner&utm_medium=email
Feb 2, 2015 ... "We hope that this study will lead to novel treatment approaches for women diagnosed with advanced stage ovarian cancer," said Jim Petrik, Ph.D.

Researchers discover ovarian cancer biomarker | ScienceDaily

http://feedproxy.google.com/~r/sciencedaily/health_medicine/~3/2F9x-R4MSyQ/140108102412.htm?utm_source=feedburner&utm_medium=email
Jan 8, 2014 ... "This helps guide treatment decisions and improve survival rates. ... 3, 2021 — Researchers demonstrate why some ovarian cancer patients ...

Scientists find genetic variants key to understanding origins of ...

http://feedproxy.google.com/~r/sciencedaily/health_medicine/ovarian_cancer/~3/m9_tDDREwJc/150615132835.htm?utm_source=feedburner&utm_medium=email
Jun 15, 2015 ... ... ovarian cancer, according to the American Cancer Society. Most ovarian cancers have low survival rates, typically because of the ...

CA2960012C - Serine proteases as biomarkers for ovarian cancer ...

https://patents.google.com/patent/CA2960012C/en
... (III/IV) because of the asymptomatic nature of the disease at stage I and early stage II. Unfortunately, the 5-year survival rate of advanced ovarian cancer ...

WO2016041932A1 - Map3k8 as a marker for selecting a patient ...

https://patents.google.com/patent/WO2016041932A1/en
In a second embodiment, the present invention relates to the use of MAP3K8 as a marker for selecting a subject affected with an ovarian cancer for a treatment ...

Elevated Levels of Lewis Y and Integrin α5β1 Correlate with ...

http://feedproxy.google.com/~r/google/GJns/~3/-Vgt_wn8EVY/15588
Multivariate COX model analysis of overall survival was performed for prognosis in ovarian carcinoma patients. ... Survival rates of the three groups of ...

Liquid biopsies offer hope for earlier treatment, better tracking of ...

http://feedproxy.google.com/~r/sciencedaily/health_medicine/ovarian_cancer/~3/0oGmju4KPLU/160720132345.htm?utm_source=feedburner&utm_medium=email
Jul 20, 2016 ... Ovarian cancer has one of the highest death rates of all gynecological cancers, because the tumor often cannot be detected until the late stages ...

US10662478B2 - Serine proteases as biomarkers for ovarian cancer

https://patents.google.com/patent/US10662478B2/en
... (III/IV) because of the asymptomatic nature of the disease at stage I and early stage II. Unfortunately, the 5-year survival rate of advanced ovarian cancer ...